PRLD

Prelude Therapeutics Incorporated

Insider Trades

NameValueActionPriceCurrent Price
Vaddi KrishnaDirector, Officer: CEO
$6.1k6.9k shares
BuyDec 19, 2024
$0.8879
--
Vaddi KrishnaDirector, Officer: CEO
$93k100k shares
BuyDec 18, 2024
$0.9321
--
Lim Bryant DavidCLO, Interim CFO, Corp Sec.
$23k25k shares
BuyDec 19, 2024
$0.9055
--
Combs AndrewChief Chemistry Officer
$3.5k3.1k shares
BuyDec 20, 2024
$1.15
--
Combs AndrewChief Chemistry Officer
$82k60k shares
BuyDec 23, 2024
$1.37
--
Vaddi KrishnaDirector, Officer: CEO
$12k10k shares
BuyDec 30, 2024
$1.20
--

News

globenewswire.comPrelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updateglobenewswire.comMay 12zacks.comWall Street Analysts Think Prelude Therapeutics (PRLD) Could Surge 33.59%: Read This Before Placing a Betzacks.comMay 8defenseworld.netFinancial Analysis: Prelude Therapeutics (NASDAQ:PRLD) versus Bioasis Technologies (OTCMKTS:BIOAF)defenseworld.netApr 27globenewswire.comPrelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offeringglobenewswire.comApr 20globenewswire.comPrelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026globenewswire.comApr 20